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The sequence of the gene encoding glycoprotein H (gH) 
of murine cytomegalovirus (MCMV) strain Smith was 
determined and compared with the sequence of the gH 
of MCMV strain K181. Transcriptional nalysis howed 
that gH is encoded by a large mRNA of 5.0 kb, which is 
synthesized late in infection. A recombinant vaccinia 
virus expressing the MCMV gH open reading frame was 
constructed (Vac-gH). Anti-MCMV serum precipitated 
a protein of 87K from Vac-gH-infected cells. Reactivity 
with a monoclonal antibody showed the identity of the 
MCMV gH with a 87K envelope glycoprotein described 
previously by Loh and Qualtiere. Immunization ofmice 
with the Vac-gH recombinant gave rise to an anti-gH 
serum, which neutralized MCMV without complement 
in vitro. 
Murine cytomegalovirus (MCMV) is a close relative of 
human cytomegalovirus (HCMV), which is a ubiquitous 
human pathogen. Most primary infections cause only 
mild if any symptoms of sickness. However, in an 
immunologically immature host, such as the fetus, as 
well as in immunocompromised individuals HCMV is a 
cause of serious illness and often death (Ho, 1991; Pass, 
1991). Because of the species specificity of HCMV, the 
availability of an appropriate animal model is important. 
MCMV is widely used as such a model because of the 
many similarities between human and routine infection 
with respect o biology and pathogenesis. 
To prevent the risks of intra-uterine HCMV infection 
attenuated virus strains are candidates for vaccines. 
Treatment of HCMV disease in immunodeficient pat- 
ients is even more difficult and presently the combined 
application of drugs and anti-HCMV antibodies is 
regarded as being most successful. To avoid the risks 
associated with live vaccines, the application of subunit 
vaccines based upon the surface glycoproteins of the 
virus has been proposed. Envelope glycoproteins of 
herpesviruses are known to be antigens for both cellular 
and humoral immune response (Spear, 1985). Their 
property of serving as targets for neutralizing antibodies 
is of particular interest. 
The nucleotide s quence r ported in this paper has been submitted to 
the GenBank database and assigned the accession number L18782. 
Two glycoproteins are known to be conserved among 
all herpesviruses, namely the glycoprotein B (gB) and the 
glycoprotein H (gH). The two glycoproteins are essential 
and probably play a role in virus entry and cell-to-cell 
spread. They are conserved in several aspects including 
genomic location of the genes, amino acid sequence, 
tertiary structure and probably function. The gB appears 
to be the major target for the host immune response 
against HCMV, and a high proportion of the neutralizing 
antibodies in human antisera re directed against gB 
(Britt et al., 1990). The recombinant protein induces a 
neutralizing antibody response (Cranage t al., 1986) and 
gB is also a target for human cytotoxic T lymphocytes 
(Borysiewicz et al., 1988). 
So far, most investigations concerning lycoproteins 
have concentrated on gB, whereas much less is known 
about gH, although it is an essential protein as well and 
capable of inducing neutralizing antibodies. Recently, 
the gH gene of the MCMV strain K181 has been 
identified and sequenced (Xu et al., 1992). After having 
characterized and expressed the gB gene (Rapp et al., 
1992) we examined the sequence and expression of the 
gH gene of the MCMV strain Smith with the intention of 
investigating the MCMV glycoproteins further in view of 
their usefulness as subunit vaccines. 
The nucleic acid sequence of the gH gene of the 
MCMV strain Smith was determined by a modified 
version of the dideoxynucleotide s quencing method 
(Tabor & Richardson, 1987). The GCG software 
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Fig, 1. Location of the gH coding region and plasmids. Top: HindlII 
cleavage map of the MCMV (Smith strain) genome. The black bar 
shows the location of the gB gene. Middle, expanded: restriction 
enzyme sites used for gH gene characterization a d cloning purposes. 
Below: the gH ORF and subclones of the HindlII C fragment are 
indicated. Primers HP1 and HP2 which were used for amplification of 
the gH ORF from the MCMV HindlII C fragment are shown as small 
black bars. 
package version 7.0 (Devereux et al., 1984) was used for 
the analysis of the nucleic acid sequence, for the 
deduction of the amino acid sequence, and for the 
comparison with the sequence of strain K181. Assuming 
no differences between the two MCMV strains regarding 
the genomic location of the gene, a 2.5 kb HindI I I -EcoRI  
fragment of the HindII I  C fragment of MCMV strain 
Smith was subcloned (pill, Fig. 1) and sequenced atthe 
EcoRI  end. The nucleotide sequence of this region 
showed 95% identity to the published K181 strain gH 
sequence. Then, a further subclone was constructed from 
the HindII I  C fragment (pH2, Fig. 1) which should 
contain the complete open reading frame (ORF). The 
DNA sequence was determined on both strands by either 
using Bal 31-generated subclones f the plasmid pH 1 or 
sequencing of pil l  and pH2 with synthetic oligo- 
nucleotide primers. The analysis revealed a single, long 
ORF of 2175 nucleotides capable of ncoding a protein 
of 725 amino acids. Thus, the gH of MCMV strain Smith 
is one amino acid longer than that of MCMV strain 
K181. The identity of the genes is 98 % on the nucleotide 
level and 95 % on the amino acid level. The differences 
are clustered in three short regions (Fig. 2). The amino 
acid exchanges in region 1 result from several differences 
in the nucleotide sequences. The differences occurring in 
regions 2 and 3 are due to short frameshifts. Besides 
these regions there are only two other amino acid 
differences. One occurs at position 322, the other at 
position 664. 
Genes of herpesviruses often show rather complicated 
transcriptional patterns as exemplified by the mRNAs of 
the HCMV and MCMV polymerase and gB genes 
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Fig. 2. (a) Comparison of parts of the nucleotide sequence of the 
MCMV strain Smith (above.) and K181 (below) gH ORFs. The three 
diverging regions are indicated. (b) Comparison of the deduced amino 
acid sequences of the MCMV strains Smith (above) and K I 81 (below) 
gH homologues. The sequences are displayed in the one-letter amino 
acid code. Only amino acid differences are shown in the K181 strain 
sequence. 
(Kouzarides et al., 1987; Elliott et al., 1991 ; Rapp et al., 
1992). To elucidate the situation for the gH gene, whole- 
cell RNA was prepared from MCMV-infected cells at 
different imes after infection following published pro- 
cedures (Chirgwin et al., 1979), and Northern blot 
hybridization was performed. A double-stranded probe 
specific for the gH region revealed two fragments of 
5-0 kb and 5.8 kb (data not shown). To discriminate 
between the gH encoding transcript and other transcripts 
of that region, strand-specific probes were prepared from 
a 1.1 kb fragment from the 3'-terminal half of the gH 
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Fig. 3. Transcriptional analysis of gH gene expression kinetics. RNA 
was prepared at different times post-infection and analysed by Northern 
blot hybridization with different strand-specific probes: (a) probe a, (b) 
probe b and (c)  probe c. Lanes 1, mock-infected; lanes 2, 4 h p.i. ; lanes 
3, 8hp. i . ;  lanes 4, 16hp. i . ;  lanes 5, 24hp. i .  in the presence of 
phosphonoacetic a id; lanes 6, 24 h p.i. Primers used for the generation 
of strand-specific probes are shown as small black bars. The arrows 
indicate the direction of the primer extension. 
ORF (Fig. 3, probes a and b) and "run-off' synthesis was 
carried out (Stfirzl & Roth, 1990). Probe a, which is 
specific for the coding strand, reacted with the 5-0 kb 
band. The probe specific for the non-coding strand (b) 
hybridized with a transcript of 5.8 kb. Probe c, which is 
located in the HindIII D fragment about 2-0 kb down- 
stream of the gH ORF (Fig. 3c) also reacted with the 
5.0 kb RNA plus an additional RNA of 3-1 kb. All 
RNAs are expressed late in infection, i.e. after 16 h post- 
infection (p.i.) (Keil et al., 1984). Since they were not 
synthesized after the DNA polymerase inhibitor phos- 
phonoacetic acid had been added to infected cells we 
conclude that the transcription of the gH gene is 
restricted to the late phase of infection. 
A vaccinia virus recombinant (Vac-gH) expressing the 
complete gH ORF was generated as follows. For the 
construction of the recombinant plasmid pCS43-gH a 
2.1 kb fragment was amplified by PCR from the HindIII 
C fragment of MCMV (Ebeling et al., 1983) using the 
primers HP1 and HP2 which included a BamHI  
restriction site for cloning purposes (Fig. 1). The 
generation of a fragment of the correct size was 
confirmed by gel electrophoresis. The fragment was 
isolated, cut with BamHI  and inserted into the vaccinia 
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Fig. 4. Detection of gH in MCMV- and Vac-gH-infected cells. Lanes 1, 
4 and 9, MCMV-infected cells; lane 2, mock-infected; lane 3, Vac- 
infected; lanes 5 and 7, VacgHl-infected; lanes 6 and 8, VacgH2- 
infected cells. Proteins were precipitated by a pre-immune serum (lane 
1), an anti -MCMV serum (lanes 7 to 9) and the monoclonal antibody 
8D1.22A (lanes 2 to 6). The position corresponding to an M r of 87K 
is indicated on the right. 
virus recombination vector pCS43 (Arnold et al., 1990) 
downstream of the vaccinia virus early-late promoter 
p7.5. The correct position of the start codon was 
confirmed by sequencing ofthe resulting plasmid pCS43- 
gH. The vaccinia virus recombinants were produced 
following established procedures (Mackett et al., 1984) 
using the DNA of vaccinia virus strain Copenhagen and 
the temperature-sensitive mutant ts7 (Drillien & Spehner, 
1983). 
To detect gH expression i  Vac-gH-infected cells two 
peptides representing amino acids 476 to 495 (PepgHI) 
and 504 to 523 (PepgHII) were selected from the deduced 
amino acid sequence of the ORF and anti-peptide sera 
were generated in rabbits. Western blotting with these 
sera confirmed the expression of the gH in Vac-gH- 
infected cells (data not shown). To characterize the gH 
gene products further, immunoprecipitations were car- 
ried out as described previously (Keil et al., 1985). 
Proteins of MCMV-infected cells were labelled with 
[3~S]methionine from 20 to 28 h p.i. Similarly, proteins of 
Vac-gH-infected cells were labelled from 4 to 8 h p.i. 
Samples of cell lysates were incubated with anti-MCMV 
serum or ascitic fluid of the monoclonal antibody 
8D1.22A (Loh & Qualtiere, 1988). The precipitated 
proteins were separated on 7"5 % SDS~olyacrylamide 
gels and visualized by fluorography. In MCMV- and 
Vac-gH-infected cells, a protein with the M r of 87K was 
recognized by the monoclonal antibody 8D1.22A (Fig. 
4). Anti-MCMV serum also precipitated a 87K protein 
from Vac-gH-infected cells. In MCMV-infected cells a 
number of proteins are recognized by this serum, among 
them a protein with an M r similar to the 87K protein 
precipitated from Vac-gH-infected cells, which probably 
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Table 1. Neutral izat ion o f  MCMV by different antisera 
Antiserum 
Reciprocal of serum dilution for 50 % 
plaque reduction 
With complement Without complement 
Anti-Vac-pp89 < 10 < 10 
Anti-Vac-gB 200-700 < 10 
Anti-Vac-gH 150-280 100-250 
Anti-MCMV 2400-2800 40 
represents he MCMV-expressed gH. The protein found 
in Vac-gH-infected cells appeared to have a slightly 
lower M r than the protein in MCMV-infected cells (Fig. 
4). The positive reaction with the neutralizing mono- 
clonal antibody 8D1.22A showed that the 87K envelope 
glycoprotein described previously (Loh & Qualtiere, 
1988) is indeed the MCMV gH. 
To determine the neutralizing capacity of an anti-gH 
serum raised in mice by infection with the Vac-gH 
recombinant a plaque reduction assay was performed as 
described previously (Rapp et al., 1992). An anti-Vac-gB 
serum and an anti-MCMV serum raised in mice by 
infection with MCMV were included in the plaque 
reduction assay for comparison. As a negative control a 
recombinant vaccinia virus expressing the immediate 
early protein pp89 was used, which does not induce a 
neutralizing antibody response (Jonjid et al., 1988). Sera 
against he vaccinia virus recombinants were generated 
by immunizing the mice intravenously with two doses of 
1 x 108 p.f.u. MCMV given 3 weeks apart. Animals were 
bled 3 weeks after the boost. Whereas the anti-Vac-pp89 
serum was not able to neutralize the virus, the anti-gH, 
anti-gB and anti-MCMV antisera showed considerable 
neutralizing activity (Table 1). The anti-gH serum was 
capable of neutralizing MCMV in the presence or 
absence of complement. The complement-independent 
neutralizing activity of the anti-gH serum was about 
fivefold higher than that of the anti-MCMV serum. 
Our data show that the sequences of the gH of the 
MCMV strains Smith and K181 are almost identical. 
The differences are clustered in three regions. The lower 
percentage of identity at the amino acid level (95%) 
compared to the nucleotide l vel (98 %) is caused by two 
small frameshifts that result in completely different 
amino sequences (Fig. 2a and b, regions 2 and 3). 
However, we cannot rule out the possibility that these 
differences are due to sequencing mistakes, since they are 
located in GC-rich regions with palindromic structures. 
We believe that our sequence is correct since it was 
obtained by sequencing both strands of this region 
several times and using deaza-dGTP to avoid compres- 
sions. The identity found between the gH of different 
MCMV strains is comparable to that found with the 
HCMV gH (Pachl et al., 1989). In the case of the MCMV 
gB the comparison of the nucleotide sequence of the 
Smith strain gB to the 3'-terminal part of the K181 strain 
gB sequence also showed a high level of identity (97 %) 
(Rapp et al., 1992; Elliott et al., 1991). However, as only 
part of the K181 strain gB sequence has been published, 
it is difficult to assess the full extent of the differences. 
For HCMV the gH sequence is more conserved between 
different strains than is the gB sequence (Chou, 1992), 
which is apparently the case for MCMV also. 
One interesting finding was that gH is encoded by a 
5.0 kb mRNA, which is about 3 kb longer than the ORF. 
The existence of additional, longer transcripts has also 
been reported for the HCMV and MCMV gB (Spaete t 
al., 1988; Rapp et al., 1992) and polymerase genes 
(Kouzarides et al., 1987; Elliott et al., 1991). It has been 
proposed that these HCMV transcripts represent read- 
through products of the gB transcript which would 
normally terminate at the polyadenylation signal within 
the DNA polymerase coding region (Kouzarides et al., 
1987). In the case of the gH no smaller transcript was 
found, and we conclude that the protein is encoded by 
the 5.0 kb transcript. That means that the gH transcript 
does not terminate at the potential polyadenylation 
signal sequence immediately downstream of the ORF as 
proposed by Xu et al. (1992) but continues through to 
the next gene and probably stops after the dUTPase 
gene. 
To conduct in vivo protection experiments the gH 
ORF was inserted into the vaccinia virus genome. The 
protein expressed by the recombinant vaccinia virus Vac- 
gH had approximately the same size (87K) as the gH 
protein in MCMV-infected cells (Fig. 4). The reaction 
with the monoclonal antibody 8D1.22A revealed the 
identity of the gH with the 87K protein described by Loh 
and Qualtiere. They have shown that this 87K protein is 
a glycoprotein and is present on the surface of the virion 
as determined by surface iodination reaction (Loh & 
Qualtiere, 1988). The small difference in size between the 
vaccinia virus-expressed gH and the authentic protein in 
MCMV-infected cells may be due to different glyco- 
sylation of the protein in Vac-gH-infected CV-1 cells in 
contrast o MCMV-infected mouse embryo fibroblasts. 
Alternatively, the difference may reflect improper pro- 
cessing of gH in Vac-gH-infected cells. Several authors 
have found that the gH homologues of other herpes- 
viruses need an accessory small protein for proper 
folding, subsequent processing and transport o the cell 
surface (Hutchinson et al., 1992; Spaete et al., 1993). 
This small glycoprotein was named gL in herpes implex 
virus (HSV) (Hutchinson et al., 1992). The vaccinia 
virus-expressed HCMV gH for example also shows a 
slightly reduced electrophoretic mobility compared to 
the authentic protein and is not transported to the cell 
surface (Cranage et al., 1988). In immunoprecipitation 
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experiments with iodinated surface proteins we also 
found no evidence for the surface expression f the 
MCMV gH in Vac-gH-infected cells (data not shown). In 
cells that co-express gH and gL, transportation of the 
HCMV gH to the cell surface can be observed (Spaete t 
al., 1993). To what extent he improper processing of the 
gH has an effect on its antigenic properties remains to be 
established. 
Typically for herpesviral gH homologues the MCMV 
gH is recognized by a monoclonal antibody (8D1.22A) 
that shows complement-independent n u ralization (Loh 
& Qualtiere, 1988). In addition, immunization with the 
Vac-gH recombinant induced considerable complement- 
independent eutralization activity in mice. In fact, the 
neutralizing capacity of the Vac-gH-induced antiserum 
was about fivefold higher than that of the anti-MCMV 
serum without complement. These results suggest that 
there are fewer anti-gH antibodies in the anti-MCMV 
serum than in the monospecific anti-gH serum. This is in 
accordance with the fact that gH is apparently less 
abundant in MCMV-infected cells than in Vac-gH- 
infected cells (data not shown). Furthermore, these data 
show that, even in the absence of the MCMV gL, the 
Vac-gH recombinant expresses the protein in a form that 
is strongly immunogenic and antigenic. This is ap- 
parently not the case for the HSV gH, because no or only 
a little neutralization activity was induced by the HSV 
gH expressed by vaccinia virus or baculovirus (Blacklaws 
et al., 1990; Forrester et aI., 1991; Ghiasi et al., 1992). 
Thus, the gL is not a stringent prerequisite for the 
formation of immunogenic domains of gH giving rise to 
neutralizing antibodies. 
Generation of the vaccinia virus recombinants Vac-gB 
and Vac-gH provides a tool for studying the immune 
response against individual glycoproteins. Since the 
experimental vaccine induces a stronger protein-specific 
in vitro neutralization than the authentic MCMV- 
expressed protein, in vivo protection experiments will 
determine the active and passive protection potential of 
the two proteins. As outlined above, the two glyco- 
proteins, especially gB, are extremely conserved inseveral 
aspects. Thus, the results of these studies will also be of 
general interest in view of the evaluation of the two 
glycoproteins as candidates for subunit vaccines. 
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